New Trial Alert: Alliance A092105 (Nasopharyngeal Cancer)

September 18, 2023

Alliance A092105: Randomized phase 2 study of nivolumab and ipilimumab with or without cabozantinib in patients with advanced nasopharyngeal carcinoma that have progressed after platinum treatment and immunotherapy

Overview: Alliance investigator Glenn J. Hanna, MD, of Dana-Farber Cancer Institute, leads this phase II trial that tests how well nivolumab and ipilimumab immunotherapy with or without cabozan

More Results From Alliance Prostate Cancer Trial - CALGB 90203

September 8, 2023

The phase III Alliance trial CALGB 90203 evaluated neoadjuvant chemohormonal therapy for high-risk localized prostate cancer before radical prostatectomy. In the Journal of the National Cancer Institute article, researchers share where they further dissected the molecular features of post-treated prostate cancer along with long-term clinical outcomes to explore mechanisms of response and resistance to che

New Trial Alert: Alliance A052101 Mantle Cell Lymphoma

September 8, 2023

Alliance A052101: A randomized phase 3 trial of continuous vs. intermittent maintenance therapy with zanubrutinib as upfront treatment in older patients with mantle cell lymphoma

Overview: Alliance investigator Anne Beaven, MD, of University of North Carolina Chapel Hill, leads this phase III trial that tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituxi

Older News